Stability of pain-related medications, metabolites, and illicit substances in urine

被引:5
作者
Gonzales, Elizabeth [1 ]
Ng, Gary [2 ]
Pesce, Amadeo [1 ]
West, Cameron [1 ]
West, Robert [1 ]
Mikel, Charles [1 ]
Latyshev, Sergey [1 ]
Almazan, Perla [1 ]
机构
[1] Millennium Res Inst, San Diego, CA 92127 USA
[2] Millennium Labs, San Diego, CA 92127 USA
关键词
Urine drug testing; Stability; Opioids; LC-MS/MS; Illicit substances; Pain; STORAGE-TEMPERATURE; WHOLE-BLOOD; DRUGS; ABUSE; SPECIMENS; MORPHINE; SERUM;
D O I
10.1016/j.cca.2012.11.020
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Effective urine drug testing requires an understanding of the stability of medications, metabolites and other substances excreted in the urine matrix. When the testing results do not fit the clinical picture, physicians frequently request repeat testing of the original specimen in order to corroborate the results. We determined the stability in urine of various medications, metabolites, and illicit substances commonly requested for testing by physicians treating patients with pain and pain-related disorders. Methods: Quantitative analyses of urine specimens were performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Two replicates at a high and low concentration were analyzed at time 0, and after 2, 3 and 6 months following storage at +4 degrees C and -20 degrees C. At each time interval, the percent difference from time 0 for each analyte was calculated and averaged for each storage condition. Results: For the majority of medications, the percent differences were within 20% of the original measurement for all 3 storage conditions. All were within 30% of the original measurement after 2, 3 and 6 months in all storage conditions, except for 7-amino-clonazepam, and carboxy-tetrahydrocannabinol. Conclusions: The findings from the current study confirm that the majority of medications, metabolites, and illicit substances commonly requested for testing by physicians treating patients with pain and pain-related disorders are stable within 20% of the original concentration when stored refrigerated or frozen for up to 6 months. Thus, delayed testing, repeat testing, and add-on testing of urine specimens can yield reliable results for up to 6 months following the urine collection date. (c) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 85
页数:6
相关论文
共 15 条
[1]   Total morphine stability in urine specimens stored under various conditions [J].
Chang, BL ;
Huang, MK ;
Tsai, YY .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2000, 24 (06) :442-447
[2]   Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain [J].
Chou, Roger ;
Fanciullo, Gilbert J. ;
Fine, Perry G. ;
Adler, Jeremy A. ;
Ballantyne, Jane C. ;
Davies, Pamela ;
Donovan, Marilee I. ;
Fishbain, David A. ;
Foley, Kathy M. ;
Fudin, Jeffrey ;
Gilson, Aaron M. ;
Kelter, Alexander ;
Mauskop, Alexander ;
O'Connor, Patrick G. ;
Passik, Steven D. ;
Pasternak, Gavril W. ;
Portenoy, Russell K. ;
Rich, Ben A. ;
Roberts, Richard G. ;
Todd, Knox H. ;
Miaskowski, Christine .
JOURNAL OF PAIN, 2009, 10 (02) :113-130
[3]  
Christo PJ, 2011, PAIN PHYSICIAN, V14, P123
[4]   Stability study of the designer drugs "MDA, MDMA and MDEX" in water, serum, whole blood, and urine under various storage temperatures [J].
Clauwaert, KM ;
Van Bocxlaer, JF ;
De Leenheer, AP .
FORENSIC SCIENCE INTERNATIONAL, 2001, 124 (01) :36-42
[5]   STABILITY OF DRUGS OF ABUSE IN URINE SAMPLES STORED AT -20-DEGREES-C [J].
DUGAN, S ;
BOGEMA, S ;
SCHWARTZ, RW ;
LAPPAS, NT .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1994, 18 (07) :391-396
[6]   Stability of benzodiazepines in whole blood samples stored at varying temperatures [J].
El Mahjoub, A ;
Staub, C .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 23 (06) :1057-1063
[7]  
FRINGS CS, 1972, CLIN CHEM, V18, P1442
[8]  
Gourlay DL, 2010, URINE DRUG TESTING C
[9]   STORAGE-TEMPERATURE EFFECT ON THE STABILITY OF MORPHINE AND CODEINE IN URINE [J].
LIN, DL ;
LIU, H ;
CHEN, CY .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1995, 19 (05) :275-280
[10]  
Parlar A, 2011, THER DRUG MONIT, V33, P491